Meacham’s manifesto to Gilead: It’s time to do something dramatic — buy, bag or burn
After watching Gilead’s pipeline falter in the second half of last year followed by a stunning forecast of rapidly shrinking revenue for its hep C franchise, Barclays senior analyst Geoff Meacham has had it. In an unusual public broadside aimed at Gilead $GILD CEO John Milligan and his executive team, Meacham threw down the gauntlet in an open letter to management, calling out plays from the bleachers designed to spur the big biotech to buy something and even possibly restructure if the numbers deteriorate much further.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.